Recruitment success for Clatterbridge prostate cancer clinical trial

Posted 19th October 2021

The research team at The Clatterbridge Cancer Centre has signed up the most participants in the UK to the PIVOTALBoost clinical trial overall – 243 since January 2018 and 12 for the last two months.

PIVOTALBoost is open to patients receiving radical radiotherapy for localised prostate cancer and is being led nationally by Clatterbridge’s Dr Isabel Syndikus, who is Chief Investigator.

The clinical trial is designed to find out if having a four-week course of radiotherapy to the prostate and lymph nodes in the pelvis or an extra boost of radiotherapy to the prostate improves the overall cancer control.

The research team wants to discover which treatment works best and causes the fewest side effects. It also intends to find out more about the quality of life of patients having the treatment.

The trial aims to recruit 1,956 patients and 12 were signed up at Clatterbridge during August and September, the most across all 41 trial sites in the UK.

Dr Syndikus said: “We are really pleased that Clatterbridge has been the highest recruiter in the UK for this important study over two consecutive months.

“I would like to thank the research team and the patients involved for achieving this.”